Earnings ·
Reports Q3 net loss of $28.5M and raises full-year revenue guidance by $50M to $1.25B-$1.3B
SRPTSarepta Therapeutics, Inc.
Sarepta Therapeutics reported third-quarter 2026 total revenues of $381.4 million, a decrease from $399.4 million in the prior year period, driven by lower ELEVIDYS sales volume due to an updated label restricting treatment to ambulatory patients. This decline was partially offset by increased contract manufacturing and collaboration revenues associated with Roche. The company reported a GAAP net loss of $28.5 million ($0.27 per diluted share) compared to a net loss of $50.6 million in the same period last year, while non-GAAP net income turned positive at $15.6 million ($0.13 per diluted share). Sarepta updated its full-year 2026 guidance, raising the low end of total net product revenue by $50.0 million to a range of $1.25 billion to $1.3 billion and narrowing expense guidance. The company also highlighted upcoming multiple ascending dose data for SRP-1003 in DM1 and SRP-1001 in FSHD expected by year-end, with preparations underway for potential Phase 3 development. Sarepta Therapeutics operates as a precision genetic medicine company focused on developing treatments for rare diseases, primarily Duchenne muscular dystrophy.